Literature DB >> 23400410

Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.

Min-Young Oh1, Joo-Seop Chung, Moo-Kon Song, Ho-Jin Shin, Ho-Sup Lee, Sang-Min Lee, Gyeong-Won Lee, Su-Ee Lee.   

Abstract

The objective of present study was to compare the prognosis of diffuse large B-cell lymphoma (DLBCL) with Waldeyer's ring involvement (WR-DLBCL) to that of nodal DLBCL (N-DLBCL) without WR involvement. Between July 2004 and October 2009, medical records and metabolic tumor volume (MTV) measured by 2-[fluorine-18]-fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography /computed tomography were collected from patients confirmed with DLBCL. All patients received six or eight cycles of R-CHOP therapy. One hundred and eight patients were included and categorized into WR-DLBCL and N-DLBCL groups. WR involvement and other prognostic factors were analyzed for survivals. High international prognostic index score and high MTV were independent poor prognostic factors. However, WR involvement was a good prognostic factor only in univariate analysis. This study suggests that tumor burden appeared to be more important than specific organ involvement for the prognosis of DLBCL.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23400410     DOI： 10.1007/s12185-013-1282-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  27 in total

1.  Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.

Authors:  Armando López-Guillermo; Luis Colomo; Mónica Jiménez; Francesc Bosch; Neus Villamor; Leonor Arenillas; Ana Muntañola; Silvia Montoto; Eva Giné; Dolors Colomer; Silvia Beà; Elías Campo; Emili Montserrat
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

2.  Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.

Authors:  Hiroyuki Takahashi; Naoto Tomita; Masahiro Yokoyama; Saburo Tsunoda; Takahiro Yano; Kayoko Murayama; Chizuko Hashimoto; Kazuo Tamura; Kazuya Sato; Yoshiaki Ishigatsubo
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

3.  Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.

Authors:  A A Ezzat; E M Ibrahim; A N El Weshi; Y M Khafaga; M AlJurf; J M Martin; D S Ajarim; S N Bazarbashi; R K Stuart; E Zucca
Journal:  Head Neck       Date:  2001-07       Impact factor: 3.147

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring.

Authors:  Y Harabuchi; H Tsubota; S Ohguro; T Himi; K Asakura; A Kataura; A Ohuchi; M Hareyama
Journal:  Acta Oncol       Date:  1997       Impact factor: 4.089

6.  Clinical analysis of malignant lymphomas of tonsils.

Authors:  S Endo; A Kida; U Sawada; M Sugitani; T Furusaka; Y Yamada; H Iida; F Sakai; S Shigihara; H Niwa; T Yamazaki; Y Kura; K Kikuchi
Journal:  Acta Otolaryngol Suppl       Date:  1996

Review 7.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

8.  FDG-PET/CT in re-staging of patients with lymphoma.

Authors:  L S Freudenberg; G Antoch; P Schütt; T Beyer; W Jentzen; S P Müller; R Görges; M R Nowrousian; A Bockisch; J F Debatin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-26       Impact factor: 9.236

9.  FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.

Authors:  Sabine Wohlfart; David Sebinger; Petra Gruber; Judith Buch; Doris Polgar; Georg Krupitza; Margit Rosner; Markus Hengstschläger; Markus Raderer; Andreas Chott; Leonhard Müllauer
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673
View more
  3 in total

1.  Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.

Authors:  Pengyue Shi; Xue Meng; Mengmeng Ni; Xindong Sun; Ligang Xing; Jinming Yu
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

2.  Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Shin Young Jeong; Sang-Min Lee; Jun-Shik Hong; Ari Chong; Joon-Ho Moon; Ji-Hyun Kim; Seok-Mo Lee; Seong Jang Kim; Ho-Jin Shin
Journal:  Cancer Sci       Date:  2013-10-23       Impact factor: 6.716

3.  Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.

Authors:  Baoping Guo; Xiaohong Tan; Qing Ke; Hong Cen
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.